Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Thiogenesis Therapeutics, Corp. has announced the European Medicines Agency’s acceptance of its Clinical Trial Application for TTI-0102, aimed at treating MELAS, a rare, inherited mitochondrial disorder with no current approved drugs. This marks a significant milestone as the company prepares to launch a Phase 2 trial in the second quarter of 2024, which will assess the efficacy and safety of TTI-0102 in a double-blind study involving 12 patients across France and the Netherlands. The excitement within Thiogenesis is palpable, as TTI-0102, patented in 2021, shows promise as a treatment for those afflicted by MELAS following a successful preliminary study.
For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.
